Cancer news - the latest biotech news from Labiotech.eu

Home Cancer Page 94

Latest Posts

xCelligence ols biosciences car t cancer cytotoxicity assay

News and Trends 12 Apr 2016

How CAR-T Cells Kill Cancer: Pictures start Moving

CAR-T is a groundbreaking personalized cancer therapy with tremendous potential to drive the patient’s own immune cells to specifically target and kill cancer cells. Because the development of this therapy is still in the early phase, new tools are needed to provide a quick potency assay to assess the cytotoxicity of the therapeutic T-cells prior […]

April 12, 2016 - 6 minutesmins - By Jerome Topsent

tunicates pharma mar sea squirt alplidin trial cancer multiple myeloma

News and Trends 7 Apr 2016

This Successful Phase III Cancer Drug comes from Sea Squirts

PharmaMar is closer to have another cancer drug on the market, after the success of phase III trials with Aplidin for Multiple Myeloma. Based in Madrid, PharmaMar is a Biopharma developing anti-cancer drugs, with an interesting strategy for drug discovery. It researches compounds present in marine organisms and assess if they have any biological action […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

metabomed ms ventures series a pfizer

News and Trends 5 Apr 2016

Israeli Cancer Startup catches Investment from 3 major Big Pharma

Metabomed is developing new highly-selective drugs that target cancer metabolism – and it has now raised €15.8M in a series A round and gotten a new CEO from Merck’s ranks. Metabomed was co-founded by MS Ventures (the VC arm of Merck KGaA) and leading researchers in the field of cancer metabolism and computational biology back in 2014. I must […]

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

biomoti oncojan physiomics virtual tumor

News and Trends 1 Apr 2016

When Nanoparticles meet Virtual Tumours to build Oncology Platform

BioMoti is enhancing cancer treatments via drug delivery innovation and it was one of the companies we visited during Labiotech Tour UK. Its Oncojan platform has caught the eye of Physiomics, a computational system biology Biotech listed on the London Stock Exchange. Oxford-based Physiomics develops computational models of cancer, allowing to simulate the effect of […]

April 1, 2016 - 3 minutesmins - By Denise Neves Gameiro

molmed biotech of the week header

News and Trends 1 Apr 2016

Biotech of the Week: MolMed, Immuno-oncology made in ‘Milano’

From one fashion capital to the other, this week we leave Paris and head down to Milan. Home to some worldwide high-fashion brands, Da Vinci’s Last Supper mural and main city of the Lombardy region, Milan is also where MolMed, our Biotech of the Week, is based. City: Milan (Italy) Founded: 1996 Employees: (+/-) 120 (as of 12/2015) […]

April 1, 2016 - 1 minutemin - By Joachim Eeckhout

affimed afmd 2015 results immuno oncology

News and Trends 31 Mar 2016

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

Affimed from Heidelberg had a ‘formative year’ (hmm) in 2015. Major highlights include raising of €52.6M, expanding to the US and advances in the development of its next-generation antibodies for immuno-oncology. Affimed is a Biopharma focused on discovering and developing highly targeted cancer immunotherapies. It is also one of our trendiest NASDAQ-listed European Biotechs (and the only one […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

immunocore uveal melanoma trial imcgp100

News and Trends 31 Mar 2016

Money Magnet Immunocore kicks off Trial for Eye Melanoma

Immunocore (UK) has enrolled its first patient for a phase I trial that will test its ImmTAC as a standalone therapy for uveal melanoma, the most common eye cancer. Immunocore is famous for having raised the biggest European Private round ever (€300M), and so it’s no wonder that if often makes our tops here at […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

epigenomics china biochain lung cancer

News and Trends 30 Mar 2016

German Biotech targets China for Lung Cancer Liquid Biopsies

Epigenomics (Germany and US) has closed a deal to develop and commercialize a new blood-based lung cancer diagnostic in China, one of its highest performing markets. There are many biotech efforts to find treatments for cancer, but a separate strategy to lower cancer mortality is to improve diagnosis – so that people can be treated when […]

March 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

gadeta cancer immuno leukemia tumours

News and Trends 30 Mar 2016

Dutch Startup gets €7M for New Cancer Immunotherapy Platform

Gadeta has raised €7M in a series A round, which will fuel the clinical development of its novel TCR platform, starting with a leukemia cell therapy trial. Gadeta is a spin-out of immuno-oncology research at the University Medical Center Utrecht (UMC Utrecht). It was founded in 2015 by the researchers and Utrecht Holdings, the technology transfer […]

March 30, 2016 - 2 minutesmins - By Denise Neves Gameiro

biotech of the week osepharma paris

News and Trends 25 Mar 2016

Biotech of the Week: OSE Pharma, the ‘Significant’ Immunotherapy Player from Paris

This week, we head up full speed from Geneva with our eyes aiming towards Paris. Known for its beauty, bohemian lifestyle and, of course the Eiffel Tower, the Louvre and le baguette, Paris is also the home of OSE Pharma, our Biotech of the Week. City: Paris (France) Founded: 2012 Employees: N/A Financial Data: €24.3M total raised (as of […]

March 25, 2016 - 2 minutesmins - By Joachim Eeckhout

autolus ucl car t series b fundraising

News and Trends 21 Mar 2016

CAR-T Startup Gets €51M from Top&New Investors

Autolus (UK) has secured over €51M in a recent series B round, led by the biggest Biotech VC in Europe – and a new player in life science investment. Autolus is a 1-year-old spin-off of the University College London (UCL) focusing on the development of next-generation CAR-T therapies, addressing current limitations of this ‘wonder therapy‘. […]

March 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

roche immuno oncology blueprint medicines boston

News and Trends 18 Mar 2016

Roche signs a €900M deal with an Immunotherapy Biotech in Boston

Roche (Switzerland) has picked 5 candidates from Blueprint Medicines (US) to complement its leading oncology pipeline. Roche is a leader in cancer therapies, but its position is threatened by intense competition, not to mention its stakes in the biosimilar war and some bad results from advanced trials. However, it seems that this Big Pharma still […]

March 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT